[HTML][HTML] Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden… - The Lancet Infectious …, 2023 - thelancet.com
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
[HTML][HTML] Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden… - The Lancet. Infectious …, 2023 - ncbi.nlm.nih.gov
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
J McLaughlin, D Malden, V Hong… - Lancet Infectious …, 2023 - escholarship.org
BACKGROUND: In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged
12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
12 years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
JA Lewnard, JM McLaughlin, D Malden, V Hong… - 2023 - cabidigitallibrary.org
Background: In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
[HTML][HTML] Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - The Lancet Infectious …, 2023 - Elsevier
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
[PDF][PDF] Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - 2023 - scholar.archive.org
Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mildto-moderate COVID-19 who are at risk of progression to severe …
years or older with mildto-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
JA Lewnard, JM McLaughlin, D Malden… - The Lancet. Infectious …, 2023 - europepmc.org
Background In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
JA Lewnard, JM McLaughlin… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
JA Lewnard, JM McLaughlin, D Malden… - The Lancet. Infectious …, 2023 - europepmc.org
Background In the USA, oral nirmatrelvir-ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …